Patients with HIV-associated dyslipidemic
lipodystrophy (HADL) have characteristic
lipid kinetic defects: accelerated lipolysis, blunted fat oxidation and increased hepatic
fatty acid reesterification. HADL patients with lipoatrophy also have
leptin deficiency. Small or non-randomized studies have suggested that
leptin replacement improves
glucose metabolism in HADL, with very limited data regarding its effects on the
lipid kinetic abnormalities. We performed a randomized, double-blind, placebo-controlled, dose-escalating (0.02 mg/kg/d for two months; 0.04 mg/kg/d for a further two months) study of the effects of
metreleptin on
lipid kinetics in 17 adults with HADL,
hypertriglyceridemia and hypoleptinemia. Rates of lipolysis, intra-adipocyte and intrahepatic reesterification and
fatty acid oxidation were measured using infusions of (13)C(1)-palmitate and (2)H(5)-glycerol, and indirect calorimetry. Fasting
lipid profiles and
glucose and
insulin responses to oral
glucose challenge were also measured.
Metreleptin treatment induced significant, dose-dependent increases in fasting plasma
leptin levels. There was no significant change in total lipolysis, net lipolysis, adipocyte or hepatic re-esterification or
fatty acid oxidation, or in fasting
triglyceride or HDL-C concentrations, with
metreleptin treatment.
Metreleptin decreased fasting non-HDL-C levels (P<.01) and area-under-the-curve for
glucose (P<.05). In hypoleptinemic HADL patients, treatment with
metreleptin at 0.02 or 0.04 mg/kg/d does not improve abnormal fasting
lipid kinetics, or
triglyceride or HDL-C levels.
Metreleptin does, however, improve glycemia and non-HDL-C in these patients. These results suggest a dissociation between
leptin's effects on
glucose metabolism compared to those on
lipid kinetics in HADL.